Parenteral drugs: FDA replaces guidance on aluminum content limits | RAPS
Regulatory NewsJoanne S. EglovitchAdvertising, Promotion and LabelingChemistry, Manufacturing and Controls (CMC)ComplianceContaminantsManufacturingNutritional/Natural HealthPharmaceuticalsQuality Assurance and ControlShortagesSterile drugsUnited StatesUS Food and Drug Administration (FDA)
